Intec Pharma (NTEC) Stock Price, News & Analysis

Company Overview

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

Key Stats

• Today's Range: N/A
• 50-Day Range: $9.15 to $36.20
• 52-Week Range: N/A
• Volume: 988,300 shs
• Average Volume: 543,436 shs
• Market Capitalization: $8.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NTEC Stock Analysis - Frequently Asked Questions

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) released its earnings results on Monday, May, 17th. The biotechnology company reported ($3.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.48) by $0.36.

When did Intec Pharma's stock split?

Intec Pharma shares reverse split before market open on Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

When did Intec Pharma IPO?

Intec Pharma (NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.

What other stocks do shareholders of Intec Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intec Pharma investors own include FuelCell Energy (FCEL), NVIDIA (NVDA), Ovid Therapeutics (OVID), Plug Power (PLUG), SCYNEXIS (SCYX), Fortress Biotech (FBIO) and Lipocine (LPCN).

Company Calendar

• Last Earnings: 5/17/2021
• Today: 11/23/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NTEC
• CUSIP: N/A
• CIK: 1638381
• Web: www.intecpharma.com
• Phone: (722) 586-4657
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($16.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,130,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -96.37%
• Return on Assets: -68.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.34
• Quick Ratio: 2.34

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.18 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 898,000
• Free Float: N/A
• Market Cap: $8.65 million
• Optionable: Optionable
• Beta: 0.83